Literature DB >> 19293271

Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkin's lymphoma treated with chemotherapy only.

Robert D van Beek1, Marry M van den Heuvel-Eibrink, Friederike G Hakvoort-Cammel, Cor van den Bos, Heleen J H van der Pal, Eric P Krenning, Yolande B de Rijke, Rob Pieters, Sabine M P F de Muinck Keizer-Schrama.   

Abstract

BACKGROUND: The aim of this study was to investigate the long-term side effects of treatment for childhood Hodgkin's lymphoma with chemotherapy only on growth, bone mineral density (BMD), body composition, and thyroid function. PROCEDURE: A total of 88 patients (56 male, 32 female; 17.6-42.6 yr), treated for childhood Hodgkin's lymphoma from 1974-1998 with combination chemotherapy adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine or epirubicin, bleomycin, vinblastine, dacarbazine with or without mechlorethamine, oncovin (vincristine), procarbazine, and prednisone (MOPP) with the intention to avoid radiotherapy, participated in this study. Median follow-up was 15.5 yr (range 5.6-30.2). BMD of lumbar spine and total body (BMD-TB), and body composition were measured using dual-energy x-ray absorptiometry. Bone mineral apparent density of the lumbar spine was calculated to correct for bone size. Free T4 and TSH were measured.
RESULTS: Men treated with MOPP had a significantly reduced height with normal body proportions. Women treated with MOPP had decreased BMD-TB and bone mineral apparent density of the lumbar spine as compared with healthy controls. Percent body fat was significantly increased in female patients treated without MOPP. Body mass index was significantly increased in male patients treated without MOPP, whereas lean body mass was normal in all patients. All patients, except one, treated with chemotherapy only had normal thyroid function. However, five patients who received additional radiation to the thyroid either had abnormal levels of TSH or free T4, or used thyroid hormones.
CONCLUSIONS: Lean body mass was normal in all patients; thyroid function was normal in all but one patient. The use of MOPP leads to decreased height and increased body mass index in men and decreased BMD-TB in women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293271     DOI: 10.1210/jc.2008-0622

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer.

Authors:  M A H den Hoed; B C Klap; M L te Winkel; R Pieters; M van Waas; S J C M M Neggers; A M Boot; K Blijdorp; W van Dorp; S M F Pluijm; M M van den Heuvel-Eibrink
Journal:  Osteoporos Int       Date:  2014-09-11       Impact factor: 4.507

2.  Bone mineral density, thyroid function, and gonadal status in young adult survivors of childhood cancer.

Authors:  Eryk Latoch; Katarzyna Muszyńska-Rosłan; Agata Panas; Anna Panasiuk; Beata Rutkowska-Żelazowska; Jerzy Konstantynowicz; Maryna Krawczuk-Rybak
Journal:  Contemp Oncol (Pozn)       Date:  2014-10-18

3.  Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management.

Authors:  Min Jae Kang; Jung Sub Lim
Journal:  Korean J Pediatr       Date:  2013-02-25

4.  Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.

Authors:  Marjolein van Waas; Sebastian J C M M Neggers; Hein Raat; Caroline M van Rij; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

5.  Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.

Authors:  Annika Englund; Charlotte Hopstadius; Gunilla Enblad; Göran Gustafsson; Gustaf Ljungman
Journal:  Acta Oncol       Date:  2014-09-09       Impact factor: 4.089

6.  Thyroid abnormalities in survivors of childhood cancer.

Authors:  Ayla Akca Çağlar; Aynur Oğuz; Faruk Güçlü Pınarlı; Ceyda Karadeniz; Arzu Okur; Aysun Bideci; Ülker Koçak; Hüseyin Bora
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.